Gerhard Lombard, Chief Financial Officer of Crescent Capital BDC, Inc. (NASDAQ:CCAP), executed a transaction on May 18, 2026, acquiring shares of the company’s common stock.
The specific details of this acquisition show that Mr. Lombard purchased 1,000 shares at a price point of $11.12 per share, resulting in a total expenditure of $11,120. This purchase activity takes place within a market context where the CCAP stock is trading close to its 52-week low of $10.92. Furthermore, the company's shares have experienced a notable decline, dropping by 14% over the preceding week.
Following this recent acquisition, Mr. Lombard’s accumulated direct ownership stake in Crescent Capital BDC reaches 37,373 shares. This total figure incorporates an additional 2,088 shares that were acquired through dividend reinvestment during 2026 and had not been previously disclosed in reporting. The company's structure remains noteworthy for its substantial dividend yield, which currently stands at 13%, a characteristic that draws attention from investors with an income-focused investment profile.
The backdrop of this insider activity is characterized by recent financial disclosures and varied expert commentary regarding the firm’s valuation. In early 2026, Crescent Capital BDC reported specific losses in its first quarter. The company recorded a loss amounting to $0.42 per share, which translated into a negative return on equity of 9.0%. Compounding this, the entity faced net realized and unrealized losses totaling $31 million, or $0.84 per share.
The financial performance data prompted several notable adjustments from major financial institutions. Oppenheimer downgraded Crescent BDC’s stock rating from Outperform to Perform. Concurrently, they also adjusted their price target, lowering it from $19 to $16. Separately, Raymond James maintained an Outperform rating but revised its price target for CCAP shares downward, setting it at $14 from the previous estimate of $15. The firm cited a broader pullback observed within sector multiples as the rationale for this adjustment.
Other analysts offered differing views on the company's current standing. Clear Street maintained a Buy rating and kept its price target set at $15.50, following the release of Crescent BDC’s fourth-quarter 2025 results. These Q4 2025 figures indicated stable pre-tax net investment income per share at $0.46. However, the company's overall investment income saw a minor decline of 1%. This dip was attributed to two factors: a contraction in the average performing debt portfolio and a corresponding decrease in the average yield.
Furthermore, B.Riley initiated coverage on Crescent Capital BDC with a Neutral rating and established a price target of $13.50. Their assessment acknowledged both the diversified nature of CCAP’s portfolio and the significant support provided by its sponsors.
In addition to these financial movements, governance updates were also reported. During its 2026 Annual Meeting, Crescent Capital BDC held proceedings where shareholders voted to elect Susan Yun Lee and Michael S. Segal as Class II Directors for three-year terms.
Risks
- The stock is trading near its 52-week low, indicating potential market weakness or investor caution.
- The company reported a negative return on equity in Q1 2026 ($0.42 loss per share) and significant net realized/unrealized losses ($31 million).
- Investment income saw a slight decline of 1% due to contraction in the average performing debt portfolio and decrease in average yield.